NCT05464329View on ClinicalTrials.gov

Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

October 31, 2029

Conditions
Large B-cell LymphomaHigh-grade B-cell LymphomaTransformed B-Cell LymphomaFollicular Lymphoma Grade 3B
Interventions
DRUG

Mosunetuzumab

Provided by Genentech.

DRUG

DHAX

-Standard of care. Flexibility in administration is permitted at the discretion of the treating physician.

DRUG

ICE

-Standard of care. Flexibility in administration is permitted at the discretion of the treating physician.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT05464329 - Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | Biotech Hunter | Biotech Hunter